About us - Euformatics

Over the past 15 years genetic sequencing costs have fallen 100x faster than computing costs. Moore’s law does not keep up.

Today, clinical genetics labs generate terabytes of sequencing data that needs to be analysed and interpreted quickly to diagnose and treat patients efficiently.

Using software, machine learning and decades of experience, we are playing our part in overcoming this challenge.

Clip: the omnomics Suite 2:12

Making NGS even more valuable

The Genomics Hub users of clinical NGS the tools to get the most out of their data. As a package or as individual software products, our tools are helping clinicians to trust their NGS data, find the most important variants for their patient and save time.

Designed with the flexibility to be used for almost any clinical domain running NGS, the Genomics Hub is helping to push the boundaries of what NGS can do for precision medicine.

Genomic regions analysed by users of Euformatics software globally

7826486261

Clinical NGS industry expected to triple within the decade

The next-generation sequencing (NGS) market is projected to reach USD 24.4 billion by 2025 from USD 7.8 billion in 2019, at a CAGR of 20.9%. The growth of this market is largely driven by the advancements in and declining costs of NGS platforms and the improving regulatory and reimbursement scenario for NGS-based diagnostic tests.

Check out the report overview

Grand View Research

Next Generation Sequencing Market Size, Share & Trends Analysis Report, February 2021

Clinical research is expected to be the fastest-growing end-use segment from 2021 to 2028.

Read the report overview

Our global distribution partner network

Are you our next partner?

We are building a global partner network to help leverage the full benefits of NGS technologies in the clinical environment. If you understand the healthcare market locally and want to include state-of-the-art clinical interpretation and quality control software in your portfolio please reach out to us.

Here are a few examples of our channel partners:

Tero Silvola

CEO

When working with the leading healthcare institutions in the world, we need to ensure that we provide the best-in-class tools for clinical geneticists so that they are able to provide better care for patients. Euformatics products complete our offering from a clinical NGS perspective and together we have delivered many high impact solutions to our customers in North America, Europe and Asia.

Eric Lee

Co-Founder and Chief Engineer

We believe that by combining omnomicsQ, the most comprehensive NGS sample quality control tool available on the market, with the analytical power of omnomicsNGS, we can ensure that laboratories running NGS in China produce impactful results, making a real difference to patient lives and the way we treat diseases.

PRESS RELEASE | Euformatics expands into the Chinese NGS market through distribution agreement with INSVAST

Henrique Vinagre

Business Director

The Euformatics offering comes at the right time for the Brazilian market, as NGS takes off and more hospitals and laboratories are looking for the right solution to make their processes simpler. OmnomicsNGS makes variant annotation and reporting easy through its flexible workflows, while omnomicsQ ensures that proper quality control is an integrated part of any NGS lab’s processes.

PRESS RELEASE | Euformatics and Síntese Biotecnologia partner for first sales channel agreement in South America

Abdul Ghani Marwan Elajou

General Manager

We believe that the omnomics Suite is the best offering on the market for our clinical customers. As the NGS market grows in Saudi Arabia and more laboratories see the value of NGS techniques, we are confident that omnomicsQ will ensure that the quality of the generated data is high while omnomicsNGS will help our medical professionals to quickly annotate and report on dangerous variants.

PRESS RELEASE | Euformatics signs distribution partnership with Illumina distributor for Saudi Arabia, Al Jeel Medical and Trading Company

What does the future hold?

202?

Common target

As Euformatics reaches the milestone of having more than a dozen customers on each major continent (excluding Antarctica), Tommi makes good on his promise to throw our ever-misbehaving printer out of the window. To be filmed and celebrated by everyone in the company 😊

Join us